IDEXX Laboratories Investor Presentation — March 2022

Document content

President and Chief Executive Officer

March 7, 2022IDEXX Laboratories, Inc.

Raymond James 43rdAnnual

Institutional Investors Conference2 © 2022 IDEXX Laboratories, Inc. All rights reserved.Safe Harbor Disclaimer

The following information contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking

statements are based on management ’s current expectations and beliefs, as well as a number of assumptions concerning future events. These statements are

subject to risks, uncertainties, assumptions and other important factors. You are cautioned not to put undue reliance on such forward -looking statements because

actual results may vary materially from those expressed or implied. The reports filed by the Company pursuant to United States securities laws contain discussions

of some of these risks and uncertainties. The Company assumes no obligation to, and expressly disclaims any obligation to, updat e or revise any forward-looking

statements, whether as a result of new information, future events or otherwise. You are advised to review the Company ’s filings with the United States Securities

and Exchange Commission (which are available from the SEC ’s EDGAR database at www.sec.gov and via the Company ’s website at www.idexx.com ).

We refer in this presentation to projections communicated at our Investor Day on August 12, 2021 and our 2022 outlook communi cated on February 2, 2022; these

references speak only as of the respective dates on which they were communicated and shall not be deemed to be a reiteration or affirmation of the guidance or an

indication that our expectations have not changed since that time.

Non-GAAP Financial Measures

In this presentation, we refer to some non-GAAP financial measures. For a reconciliation to the most comparable GAAP financial measures, we refer you to our

footnotes and the Appendix to this presentation, which also refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2021, both

available at www.idexx.com/investors .

Please refer to additional footnotes in the Appendix.

3 © 2022 IDEXX Laboratories, Inc. All rights reserved.

IDEXX Focus: Increasing Companion Animal Healthcare Globally Through

Innovation, Insight and Customer -focused Engagement

Decades+ opportunity to increase

standard of care (~$37 billion TAM)

Innovation delivering best -in-class,

integrated diagnostic and software solutions

Global commercial capability and multi-modality offering advancing adoption